Medtronic (MDT)

Medtronic grew revenue by 14% in the first quarter of its fiscal 2027.

Consumers don't stop buying vital products during bear markets, which is why healthcare and consumer staples stocks are smart investments.

Pediatrix Medical Group (NYSE:MD) reported third-quarter 2026 adjusted EBITDA of $85 million, with management saying results exceeded its expectations despite rising costs across healthcare delivery. The company narrowed its full-year adjusted EBITDA outlook to a range of $290 million to $300 millio

Today, Oct. 28, 2026, the medical device maker slashed profit expectations after an August cyberattack continued disrupting operations.

Intuitive Surgical posted Q3 margin impairments from a legal settlement and pricing changes, but revenue grew 21.5%, guidance firmed, and analysts and institutions remain bullish on ISRG.

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

A recent spinoff could pave the way for greater dividend growth.

The company's board of directors can play a vital role in positioning the company to develop the next generation of aircraft.

Two healthcare stocks that are leading their niches, and two that investors aren't giving enough credit to in the same niches.

The medical device giant deserves a lot more attention.

People have long been willing to pay for healthcare despite rising costs, with Medtronic and Eli Lilly offering two different angles on the space.

AbbVie and Medtronic are both stable blue chip dividend plays in this choppy market.

These companies haven't said their last words.

Investors aren't giving Medtronic credit for its turnaround, and McCormick is gearing up for a major business expansion.

Rising interest rates are unlikely to change the dynamics in the healthcare sector, where people are willing to pay for care.